Lifecore Biomedical, Inc. (LFCR)
(Real Time Quote from BATS)
$4.99 USD
+0.14 (2.89%)
Updated Jul 22, 2024 11:04 AM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
LFCR 4.99 +0.14(2.89%)
Will LFCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LFCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LFCR
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?
LFCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3
Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should Know
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
Other News for LFCR
Laughing Water Capital Q2 2024 Letter
Enzo Biochem: Is This Time Finally Different?
Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Graham & Doddsville Spring 2024 Newsletter From Columbia Business School